Holen Sie sich die Stockscreener-App
0.00
100.00%
-9.50
Schlusskurs vom Vortag:
$9.50
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$925.93M
Einnahmen:
$64.70M
Nettoeinkommen (Verlust:
$-123.43M
KGV:
0.00
EPS:
-1.38
Netto-Cashflow:
$-95.23M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$9.67
Poseida Therapeutics Inc Stock (PSTX) Company Profile
Firmenname
Poseida Therapeutics Inc
Sektor
Branche
Telefon
858-779-3100
Adresse
9390 TOWNE CENTRE DRIVE, SAN DIEGO
Vergleichen Sie PSTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PSTX
Poseida Therapeutics Inc
|
0.00 | 925.93M | 64.70M | -123.43M | -95.23M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.42 | 124.91B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.85 | 60.05B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
594.65 | 35.88B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.97 | 29.83B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.13 | 24.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Poseida Therapeutics Inc Stock (PSTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-01-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-05-18 | Eingeleitet | BTIG Research | Buy |
| 2020-08-04 | Eingeleitet | BofA Securities | Buy |
| 2020-08-04 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-04 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Poseida Therapeutics Inc Aktie (PSTX) Neueste Nachrichten
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors - GlobeNewswire
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2022 - marketscreener.com
Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum - MarketScreener
Allogeneic CAR-T Cell Patent Landscape and Forecast Report - GlobeNewswire
Allogeneic CAR-T Cell Patent Landscape and Forecast Report 2024-2032, Profiles of Artiva Biotherapeutics, Poseida Therapeutics, Nanjing Beiheng Biological Technology, NantCell, GC Cell, BMS, Compugen - GlobeNewswire
Dealmaking Quarterly Statistics, Q4 2024 - insights.citeline.com
SG Americas Securities LLC Boosts Stake in Poseida Therapeutics, Inc. (NASDAQ:PSTX) - Defense World
Poseida Therapeutics, Inc. (NASDAQ:PSTX) Holdings Raised by JPMorgan Chase & Co. - Defense World
Roche to complete $1.5 billion acquisition of U.S. biopharma company Poseida - MSN
Poseida Therapeutics, Inc. (NASDAQ:PSTX) Shares Acquired by Barclays PLC - Defense World
Roche to close $1.5B acquisition of Poseida Therapeutics - MSN
Jane Street Group LLC Has $296,000 Holdings in Poseida Therapeutics, Inc. (NASDAQ:PSTX) - Defense World
Poseida Therapeutics Completes Merger with Roche Holdings, Inc. and Blue Giant Acquisition Corp. - Defense World
Poseida Therapeutics acquired by Roche Holdings - Investing.com Australia
Roche Finalizes Poseida Acquisition: This Cell Therapy Deal Feels Like A Win/Win (RHHBY) - Seeking Alpha
Major pharmaceutical company Roche buys cell and gene developer Poseida Therapeutics in $1.5 billion acquisition - BioProcess Insider
Poseida Therapeutics acquired by Roche Holdings By Investing.com - Investing.com South Africa
Roche completes tender offer for Poseida Therapeutics shares By Investing.com - Investing.com Canada
Roche Completes Biopharma Acquisition Worth Up To $1.5B - Law360
Poseida Therapeutics Undergoes Merger and Delisting Changes - TipRanks
Roche set to finalise $1.5bn Poseida Therapeutics takeover - Proactive Investors USA
Roche Finalizes Tender Offer for $1.5B Poseida Deal - TipRanks
Roche: Poseida acquisition nears completion -January 08, 2025 at 04:55 am EST - Marketscreener.com
Roche completes tender offer for Poseida Therapeutics shares - Investing.com India
Roche Completes Acquisition of Poseida TherapeuticsNews and Statistics - IndexBox, Inc.
Roche to close $1.5B acquisition of Poseida Therapeutics (OTCQX:RHHBY) - Seeking Alpha
Roche Acquires Poseida, Boosting Malin’s Financial Returns - TipRanks
Roche to complete acquisition of U.S. biopharma company Poseida - MSN
Roche to complete acquisition of U.S. biopharma company Poseida -January 08, 2025 at 01:35 am EST - Marketscreener.com
Roche purchases shares in tender offer for Poseida Therapeutics, Inc. - The Manila Times
Roche Completes Major Acquisition of Poseida Therapeutics with 66% Share Tender Success - StockTitan
Poseida Therapeutics (NASDAQ:PSTX) Reaches New 1-Year HighHere's What Happened - MarketBeat
Poseida announces US waiting period expiration for deal with Roche - MLex
Geode Capital Management LLC Sells 5,438 Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) - Defense World
Poseida Therapeutics, Inc. (NASDAQ:PSTX) Shares Bought by Barclays PLC - MarketBeat
Poseida Therapeutics, Inc. (NASDAQ:PSTX) Shares Purchased by Barclays PLC - Defense World
Poseida Therapeutics (NASDAQ:PSTX) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Poseida Therapeutics stock soars to 52-week high of $9.59 By Investing.com - Investing.com Australia
Poseida Therapeutics (NASDAQ:PSTX) Sets New 1-Year HighHere's Why - MarketBeat
Poseida Therapeutics stock soars to 52-week high of $9.59 - Investing.com
PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders - Business Wire
Wellington Management Group LLP Reduces Position in Poseida Therapeutics, Inc. (NASDAQ:PSTX) - MarketBeat
Poseida Therapeutics (NASDAQ:PSTX) Sets New 52-Week HighHere's What Happened - MarketBeat
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, PSTX, AE, PFIE on Behalf of Shareholders - PR Newswire
$TOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of PFIE, PSTX, ARCH, B to Take Action - PR Newswire
Poseida Therapeutics, Inc. (PSTX) Hits Fresh High: Is There Still Room to Run? - MSN
XTX Topco Ltd Increases Stake in Poseida Therapeutics, Inc. (NASDAQ:PSTX) - MarketBeat
Finanzdaten der Poseida Therapeutics Inc-Aktie (PSTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.69%
21.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):